Swedish Exchange Growth Leaders With High Insider Stakes

As global markets navigate through a landscape marked by fluctuating inflation rates and cautious monetary policies, Sweden's stock market presents a unique blend of opportunities, particularly in growth companies with high insider ownership. These firms often benefit from aligned interests between shareholders and management, potentially leading to more resilient performance in uncertain economic times.

Top 10 Growth Companies With High Insider Ownership In Sweden

Name	Insider Ownership	Earnings Growth
CTT Systems (OM:CTT)	16.9%	21.6%
BioArctic (OM:BIOA B)	35.1%	50.5%
Sileon (OM:SILEON)	33.3%	109.3%
Calliditas Therapeutics (OM:CALTX)	11.6%	50.3%
InCoax Networks (OM:INCOAX)	18%	104.9%
KebNi (OM:KEBNI B)	37.8%	90.4%
edyoutec (NGM:EDYOU)	14.6%	63.1%
Egetis Therapeutics (OM:EGTX)	17.6%	98.2%
Yubico (OM:YUBICO)	37.5%	42.5%
SaveLend Group (OM:YIELD)	24.9%	106.8%

Click here to see the full list of 85 stocks from our Fast Growing Swedish Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

BioArctic

Simply Wall St Growth Rating: ★★★★★★

Overview: BioArctic AB (ticker: OM:BIOA B) is a Swedish biopharmaceutical company focused on developing biological drugs for central nervous system disorders, with a market capitalization of approximately SEK 21.85 billion.

Operations: The company generates revenue through the development of biological drugs targeting central nervous system disorders.

Insider Ownership: 35.1%

Earnings Growth Forecast: 50.5% p.a.

BioArctic, a Swedish biopharma company, is trading at 63% below its estimated fair value and is poised for significant growth with expected revenue increases of 40.7% per year, outpacing the Swedish market's 2.1%. Although insider buying hasn't been substantial in recent months, the forecast for profitability within three years alongside a high anticipated return on equity (31.7%) highlights its potential. Recent approvals in South Korea for its Alzheimer's treatment Leqembi® underscore BioArctic’s strategic advances in neurodegenerative diseases.

• Get an in-depth perspective on BioArctic's performance by reading our analyst estimates report here.

• Insights from our recent valuation report point to the potential undervaluation of BioArctic shares in the market.

OM:BIOA B Ownership Breakdown as at Jun 2024

Medicover

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Medicover AB operates in the healthcare and diagnostic services sector, serving clients in Poland, Sweden, and internationally, with a market capitalization of approximately SEK 29.69 billion.

Operations: The company generates revenue primarily through two segments: Diagnostic Services, which brought in €585.20 million, and Healthcare Services, accounting for €1.26 billion.

Insider Ownership: 11.1%

Earnings Growth Forecast: 38.2% p.a.

Medicover, a Swedish healthcare provider, reported substantial earnings growth of 1492.9% over the past year and is set to continue this trend with forecasted annual earnings and revenue growth of 38.2% and 14.5%, respectively, outstripping the Swedish market averages. Despite trading at 51.3% below its estimated fair value and facing challenges with interest coverage, recent corporate guidance predicts organic revenue exceeding €2.2 billion by year-end 2025, reflecting strong operational momentum.

• Take a closer look at Medicover's potential here in our earnings growth report.

• Our valuation report here indicates Medicover may be overvalued.

OM:MCOV B Ownership Breakdown as at Jun 2024

Pandox

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pandox AB is a hotel property company that specializes in owning, operating, and leasing hotel properties, with a market capitalization of approximately SEK 35.19 billion.

Operations: The company generates its revenue primarily through two segments: own operation, which brought in SEK 3.24 billion, and rental agreements, contributing SEK 3.76 billion.

Insider Ownership: 12.3%

Earnings Growth Forecast: 46.3% p.a.

Pandox, a Swedish hotel operator, has shown a robust recovery with first-quarter sales rising to SEK 812 million from SEK 743 million the previous year and net income turning positive at SEK 447 million compared to a loss last year. Despite this, its profit margins have declined sharply to 1.1% from last year’s 49.2%. The company is expected to see earnings grow by an impressive rate annually over the next three years, outpacing the Swedish market significantly. However, interest payments are poorly covered by earnings and recent insider buying has not been substantial.

• Click to explore a detailed breakdown of our findings in Pandox's earnings growth report.

• Our valuation report unveils the possibility Pandox's shares may be trading at a discount.

OM:PNDX B Ownership Breakdown as at Jun 2024

Turning Ideas Into Actions

• Click this link to deep-dive into the 85 companies within our Fast Growing Swedish Companies With High Insider Ownership screener.

• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.

• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include OM:BIOA BOM:MCOV B OM:PNDX B and

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com